EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Efficacy of varenicline or bupropion and its association with nicotine metabolite ratio among smokers with COPD

Rui Qin, Zhao Liu iD, An-Qi Cheng, Xin-Mei Zhou, Zheng Su, Zi-Yang Cui iD, Jin-Xuan Li, Xiao-Wen Wei, Liang Zhao, Kian Fan Chung iD, Dan Xiao iD, Chen Wang

Respirology · 2024

DOI: 10.1111/resp.14702 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Respirology, 2024. Verfasst von Rui Qin und 11 weiteren Autor:innen. Beteiligte Einrichtung: China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Varenicline, Bupropion, Pulmonary Disease, Chronic Obstructive, Smoking Cessation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine, Science and Technology Project of Heilongjiang Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objective Nicotine metabolic ratio (NMR) has been associated with nicotine metabolism and smoking characteristics. However, there are few studies on the potential association between NMR and smoking cessation efficacy in smokers with chronic obstructive pulmonary disease (COPD) in China or elsewhere. Methods This study was a stratified block randomized controlled trial for smoking cessation in Chinese smokers with COPD. NMR was used as a stratification factor; slow metabolizers were defined as those with NMR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VareniclineBupropionPulmonary Disease, Chronic ObstructiveSmoking CessationSmoking Cessation AgentsNicotineHumansMaleFemaleMiddle AgedTreatment OutcomeAgedChinaSmokers

Stichwörter der Autor:innen

Chinachronic obstructive pulmonary diseasenicotine metabolic ratiosmoking cessation

Substanzen

VareniclineBupropionSmoking Cessation AgentsNicotine

Autor:innen und Institutionen

  • China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Tobacco Control and Prevention of Respiratory Disease, China-Japan Friendship Hospital, Beijing, China.
  • WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention, Beijing, China.
  • National Clinical Research Center for Respiratory Diseases, Beijing, China.
  • Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • National Center for Respiratory Medicine, Beijing, China.

ORCID-Profile: Zhao Liu, Zi-Yang Cui, Kian Fan Chung, Dan Xiao

Förderung

  • National High Level Hospital Clinical Research Funding
  • Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine
  • Science and Technology Project of Heilongjiang Province of China

Zitieren

APA

Qin, R., Liu, Z., Cheng, A. Q., Zhou, X. M., Su, Z., Cui, Z. Y., Li, J. X., Wei, X. W., Zhao, L., Chung, K. F., Xiao, D., & Wang, C. (2024). Efficacy of varenicline or bupropion and its association with nicotine metabolite ratio among smokers with COPD. Respirology. https://doi.org/10.1111/resp.14702

Vancouver

Qin R, Liu Z, Cheng AQ, Zhou XM, Su Z, Cui ZY, et al. Efficacy of varenicline or bupropion and its association with nicotine metabolite ratio among smokers with COPD. Respirology. 2024. doi:10.1111/resp.14702

BibTeX
@article{Qin2024,
  author = {Qin, Rui and Liu, Zhao and Cheng, An-Qi and Zhou, Xin-Mei and Su, Zheng and Cui, Zi-Yang and Li, Jin-Xuan and Wei, Xiao-Wen and Zhao, Liang and Chung, Kian Fan and Xiao, Dan and Wang, Chen},
  title = {Efficacy of varenicline or bupropion and its association with nicotine metabolite ratio among smokers with COPD},
  journal = {Respirology},
  year = {2024},
  doi = {10.1111/resp.14702}
}
Kostenlos starten →